Financial reports
10-Q
2020 Q3
Quarterly report
12 Feb 21
10-Q
2020 Q2
Quarterly report
2 Nov 20
10-Q
2020 Q1
Quarterly report
13 Aug 20
10-K
2020 FY
Annual report
19 Jun 20
10-Q
2020 Q3
Quarterly report
13 Feb 20
10-Q
2020 Q2
Quarterly report
7 Nov 19
10-Q
2020 Q1
Quarterly report
14 Aug 19
10-K
2019 FY
Annual report
14 Jun 19
10-Q
2019 Q3
Quarterly report
14 Feb 19
10-Q
2019 Q2
Quarterly report
13 Nov 18
Current reports
8-K
Sumitovant Biopharma Completes Acquisition of Urovant Sciences
29 Mar 21
8-K
Submission of Matters to a Vote of Security Holders
24 Mar 21
8-K
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
12 Feb 21
8-K
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
11 Feb 21
8-K
Entry into a Material Definitive Agreement
9 Feb 21
8-K
GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences
23 Dec 20
8-K
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of
24 Nov 20
8-K
Regulation FD Disclosure
17 Nov 20
8-K
Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
13 Nov 20
8-K
Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
2 Nov 20
Registration and prospectus
15-12B
Securities registration termination
8 Apr 21
SC 13E3/A
Going private transaction (amended)
29 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 21
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Mar 21
POS AM
Prospectus update (post-effective amendment)
29 Mar 21
25-NSE
Exchange delisting
29 Mar 21
SC 13E3/A
Going private transaction (amended)
19 Feb 21
SC 13E3/A
Going private transaction (amended)
9 Feb 21
SC 13E3
Going private transaction
29 Dec 20
Proxies
DEFM14A
Proxy related to merger
19 Feb 21
PRER14A
Preliminary revised proxy
2 Feb 21
PREM14A
Preliminary proxy related to merger
29 Dec 20
DEFA14A
Additional proxy soliciting materials
16 Nov 20
DEFA14A
Additional proxy soliciting materials
13 Nov 20
DEFA14A
Additional proxy soliciting materials
13 Nov 20
DEFA14A
Additional proxy soliciting materials
12 Nov 20
DEFA14A
Additional proxy soliciting materials
12 Nov 20
DEFA14A
Additional proxy soliciting materials
27 Jul 20
DEF 14A
Definitive proxy
27 Jul 20
Other
EFFECT
Notice of effectiveness
1 Apr 21
UPLOAD
Letter from SEC
16 Feb 21
CORRESP
Correspondence with SEC
2 Feb 21
UPLOAD
Letter from SEC
19 Jan 21
EFFECT
Notice of effectiveness
27 Nov 19
CORRESP
Correspondence with SEC
22 Nov 19
UPLOAD
Letter from SEC
20 Nov 19
CT ORDER
Confidential treatment order
27 Sep 18
CERT
Certification of approval for exchange listing
26 Sep 18
EFFECT
Notice of effectiveness
26 Sep 18